Table 1.
Covariate Distributions in NSABP B-14 and TransATAC Meta-Analysis Evaluable Patients (n = 1,735)
| Covariate | NSABP B-14 (n = 647) |
TransATAC (n = 1,088) |
||
|---|---|---|---|---|
| No. | % | No. | % | |
| RS | ||||
| Median | 17 | 16 | ||
| 1st-3rd quartile | 11-31 | 11-24 | ||
| Tumor grade | ||||
| Well differentiated | 224 | 35 | 242 | 22 |
| Moderately differentiated | 293 | 45 | 655 | 60 |
| Poorly differentiated | 130 | 20 | 191 | 18 |
| Tumor size, cm | ||||
| Median | 2.0 | 1.8 | ||
| 1st-3rd quartile | 1.3-2.5 | 1.2-2.3 | ||
| Age at surgery, years | ||||
| Median | 58 | 63 | ||
| 1st-3rd quartile | 48-65 | 57-70 | ||
| Hormonal therapy | ||||
| Tamoxifen alone | 647 | 100 | 540 | 50 |
| Anastrozole alone | — | 548 | 50 | |
| Nodal status | ||||
| No positive nodes (N0) | 647 | 100 | 797 | 73 |
| 1-3 positive nodes (N1-3) | — | 235 | 22 | |
| 4+ positive nodes (N4+) | — | 56 | 5 | |
Abbreviations: NSABP, National Surgical Adjuvant Breast and Bowel Project; RS, Recurrence Score; TransATAC, translational research cohort of Arimidex, Tamoxifen Alone or in Combination trial.